AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, ...
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...
Pharmaceutical Technology on MSN
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
The company is embracing AI integration throughout drug development, aiming to improve efficiency and drive portfolio ...
AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...
Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...
Bloomberg on MSN
AstraZeneca CFO on M&A strategy and obesity market
AstraZeneca CFO Aradhana Sarin discusses the company's M&A strategy and weight-loss portfolio with Katie Greifeld at the ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...
Pharmaceutical Technology on MSN
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery
The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...
AstraZeneca PLC aims for $80 billion in revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback